Showing 241-250 of 4926 results for "".
The Complete Guide to Launching a New Treatment
https://practicaldermatology.com/topics/practice-management/the-complete-guide-to-launching-a-new-treatment/23551/Learn how one cosmetic dermatology office successfully launched more than 40 new treatments in 2020 with plans to double that number by the end of 2021.Analyzing Safety Data From Level Up
https://practicaldermatology.com/series/the-practical-dermatology-podcast/analyzing-safety-data-from-level-up/33944/The latest news and updates, plus Matthew Zirwas, MD, FAAD, joins Practical Dermatology Chief Medical Editor Neal Bhatia, MD, FAAD, to discuss the importance of the Week 16 safety data from the Level Up study on upadacitinib. Silverberg JI, Bunick CG, et al. Efficacy and safety of upadacitinib versuUsing Life Insurance to Build and Protect Wealth
https://practicaldermatology.com/topics/practice-management/using-life-insurance-to-build-and-protect-wealth/23810/A look at the role life insurance can play in providing solutions for retirement planning and wealth accumulation.Anti-OX40 Ligand Antibody Trials
https://practicaldermatology.com/series/updates-atopic-dermatitis/anti-ox40-ligand-antibody-trials/29531/Lead study author Stephan Weidinger, MD, PhD, Director of the Department of Dermatology and Allergy at the University Hospital Schleswig-Holstein, discusses the phase 2b STREAM-AD trial, evaluating amlitelimab in adult patients with moderate-to-severe atopic dermatitis.Emrosi Launched in the US for Rosacea
https://practicaldermatology.com/series/dermwire-tv/emrosi-launched-in-the-us-for-rosacea/33943/In this week's DermwireTV, a new treatment for rosacea is launched in the US; long-term data is presented for tapinarof 1% cream for atopic dermatitis; and in our C-Suite Chats segment, we speak with the CEO and Co-Founder of Mama Sol.I Came In Like a Wrecking Ball
https://practicaldermatology.com/issues/practicaldermatology-com-march-2025/i-came-in-like-a-wrecking-ball/33162/I have to start by warning you, dear reader, that I am writing my first editorial for Practical Dermatology immediately after typing up four appeal letters to insurance companies.ISDPA: Dr. Lal on Therapeutic Updates
https://practicaldermatology.com/conferences/isdpa-midwest-derm-2024/isdpa-dr-lal-therapeutic-updates/29149/Karan Lal, DO, discusses the latest therapeutic updates for atopic dermatitis and other conditions, including his strategies for utilizing dupilumab, at the Illinois Society of Dermatology Physician Assistants (ISDPA) Midwest Dermatology Conference 2024.Chronic Hand Eczema Treatment Landscape
https://practicaldermatology.com/series/c-suite-chats/chronic-hand-eczema-treatment-landscape/29126/Jacob Thyssen, MD, PhD, Chief Scientific Officer at Leo Pharma, talks about the incidence of chronic hand eczema and the advantage that delgocitinib provides compared to other treatment options.Advanced Laser Techniques from Cosmetic Surgery Forum 2019
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/advanced-laser-techniques-1/20125/What are the most promising energy-based options in laser technology. CSF faculty members, Jill Waibel, MD, Neil Sadick, MD, Manjula Jegasothy, MD, an Barry Lycka, MD offer fresh takes on the device field and share tips for optimizing outcomes.DermWireTV: PCA to Space Station; ASDS Pandemic Data; LaRoche-Posay, GW Partnership
https://practicaldermatology.com/topics/practice-management/dermwiretv-pca-to-space-station-asds-pandemic-data-laroche-posay-gw-partnership/20059/The "Great Resignation" forcing some dermatology practices to operate with reduced staffing is just one of the lingering impacts of the COVID-19 pandemic on practices, according to results of a survey by the American Society for Dermatologic Surgery. PCA skin is sending the first-ever private sector